{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 16 of 92', 'CR845-CLIN3103', '2.0', 'Table of Contents', '1.0 Protocol Synopsis', '4', '2.0 Table of Contents', '16', '3.0 List of Abbreviations', '21', '4.0 Introduction', '22', '4.1', 'Background and Rationale', '22', '4.2', 'Clinical Experience', '23', '4.2.1', 'Overall Exposure', '23', '4.2.2', 'Safety in Hemodialysis Patients', '23', '4.2.3', 'Efficacy of CR845 in Hemodialysis Patients with Uremic Pruritus', '24', '4.2.4', 'Pharmacokinetics in Hemodialysis Patients', '25', '4.3', 'Summary of Potential Risks and Benefits', '25', '5.0 Objectives', '27', '6.0 Investigational Plan', '28', '6.1', 'Overall Study Design and Plan: Description', '28', '6.1.1', 'Double-blind Phase', '28', '6.1.1.1', 'Screening Visit', '28', '6.1.1.2', 'Run-in Period', '28', '6.1.1.3', 'Double-blind Treatment Period', '29', '6.1.2', 'Open-label Extension Phase', '30', '6.1.3', 'Follow-up Period', '30', '6.2', 'Selection of Study Population', '33', '6.2.1', 'Inclusion Criteria', '33', '6.2.2', 'Exclusion Criteria', '35', '6.3', 'Removal of Patients from Therapy or Assessment', '36', '6.3.1', 'Discontinuation of Individual Patients', '36', '6.3.2', 'Discontinuation or Suspension of Entire Study', '37', '6.4', 'Treatments', '38', '6.4.1', 'Treatments Administered', '38', '6.4.2', 'Identity of Investigational Product(s)', '38', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 17 of 92', 'CR845-CLIN3103', '6.4.2.1', 'Formulation of Study Drug', '38', '6.4.2.2', 'Packaging, Labeling, and Storage Stability of Study Drug', '39', '6.4.2.3', 'Individual Dose Labeling', '39', '6.4.3', 'Drug Accountability', '39', '6.4.4', 'Method of Assigning Patients to Treatment Groups', '39', '6.4.5', 'Preparation of CR845', '40', '6.4.6', 'Management of Missed Doses', '40', '6.4.7', 'Treatment Compliance', '40', '6.4.8', 'Blinding', '40', '6.4.9', 'Prior, Concomitant, and Prohibited Medications', '41', '6.4.9.1', 'Prior and Concomitant Medications', '41', '6.4.9.2', 'Restricted and Prohibited Medications', '41', '6.5', 'Study Assessments and Procedures', '42', '6.5.1', 'Schedule of Events for the Double-blind Phase', '42', '6.5.2', 'Schedule of Events for the Open-label Extension Phase', '46', '6.5.3', 'Efficacy Assessments', '50', '6.5.3.1 Worst Itching Intensity Numerical Rating Scale', '50', '6.5.3.2', 'Skindex-10 Scale', '50', '6.5.3.3', '5-D Itch Scale', '50', '6.5.3.4', 'Patient Global Impression of Change', '51', '6.5.4', 'Safety Assessments', '51', '6.5.4.1', 'Adverse Events', '51', '6.5.4.2', 'Structured Safety Evaluation', '55', '6.5.4.3', 'Physical Examination', '55', '6.5.4.4', 'Vital Signs', '55', '6.5.4.5', 'Electrocardiogram', '56', '6.5.4.6', 'Clinical Laboratory Tests', '56', '6.5.4.7', 'Contraception and Pregnancy', '57', '6.5.5', 'Additional Assessments', '57', '6.5.5.1', 'Inflammatory Biomarkers', '58', '6.5.5.2', 'Missed Dialysis Visits', '58', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}